|
|Section2= }} Morphine-''N''-oxide (genomorphine) is an active opioid metabolite of morphine. Morphine itself, in trials with rats, acts 11–22 times more potent than morphine-''N''-oxide subcutaneously and 39–89 times more potent intraperitoneally. However, pretreatment with amiphenazole or tacrine increases the potency of morphine-''N''-oxide in relation to morphine (intraperitoneally more so than in subcutaneous administration). A possible explanation is that morphine-''N''-oxide is rapidly inactivated in the liver and impairment of inactivation processes or enzymes increases functionality. Morphine-''N''-oxide can also form as a decomposition product of morphine outside the body and may show up in assays of opium and poppy straw concentrate. Codeine and the semi-synthetics such as heroin, dihydrocodeine, dihydromorphine, hydromorphone, and hydrocodone also have equivalent amine oxide derivatives. Morphine-''N''-Oxide has a DEA ACSCN of 9307 and annual production quota of 655 grammes in 2013. It is a Schedule I controlled substance in the US.〔http://www.deadiversion.usdoj.gov/fed_regs/quotas/2013/fr0620.htm〕 ==See also== * Codeine-''N''-oxide * Morphine-6-glucuronide * Morphine-3-glucuronide 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Morphine-N-oxide」の詳細全文を読む スポンサード リンク
|